Sign in

    Nick Abbott

    Senior Sell Side Biotech Analyst at Wells Fargo & Company

    Nick Abbott is a Senior Sell Side Biotech Analyst at Wells Fargo Securities, specializing in biotechnology equity research and analysis. He has covered notable biotech companies such as Cellectis, Affimed, ZIOPHARM Oncology, and Calithera Biosciences, and his analyst calls have included both buy and downgrade ratings with a total of 10 ratings tracked; however, his overall average return has been -33.8%, ranking in the 6th percentile among peers according to public performance data. Abbott's recent roles include leading Wells Fargo’s biotech equity research, with a clear focus on immunotherapy and genetic medicine firms, and he has previously held roles of increasing responsibility within the field. He is recognized for his expertise in biotech equities, with his professional credentials likely to include standard FINRA registrations and securities licenses required for his senior role, although specific license numbers are not publicly stated.

    Nick Abbott's questions to Lite Strategy (MEIP) leadership

    Nick Abbott's questions to Lite Strategy (MEIP) leadership • Q4 2022

    Question

    Nick Abbott of Wells Fargo inquired about the timing of data from Kyowa Kirin's Japanese trial of zandelisib, whether MEI has formally proposed revisions to the COASTAL study to the FDA, and the company's interest in a recent publication on intermittent PI3K delta inhibitor dosing in head and neck cancer.

    Answer

    SVP David Walsey stated that partner Kyowa Kirin has not set a public timeline for its Japanese data but intends to file for full approval. He also confirmed MEI has not yet made a formal proposal to the FDA on COASTAL, as they are conducting complex analysis to ensure a meaningful discussion. CEO Dan Gold added that the company was 'heartened' by the recent head and neck cancer publication, which supports their intermittent dosing strategy, and said to 'stay tuned' for potential exploration in that area.

    Ask Fintool Equity Research AI